OMEROS CORP
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
OMER$17.30-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
1. Financial Statements
See the Index to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K.
2. Financial Statement Schedules
All schedules have been omitted as the required information is either not required, not applicable or otherwise included in the Financial Statements and notes thereto.
3. Exhibits
The following list of exhibits includes exhibits submitted with this Form 10-K as filed with the SEC and those incorporated by reference to other filings.
EXHIBIT INDEX
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit No. · Exhibit Description · Form · File No. · Exhibit No. · Filing Date · Filed Herewith | |||||
| 1.1 | Sales Agreement, dated March 1, 2021, between Omeros Corporation and Cantor Fitzgerald & Co. | 10-K | 001-34475 | 1.1 | 03/01/2021 |
| 3.1 | Amended and Restated Articles of Incorporation of Omeros Corporation | 10-K | 001-34475 | 3.1 | 03/31/2010 |
| 3.2 | Amended and Restated Bylaws of Omeros Corporation | 10-K | 001-34475 | 3.2 | 03/31/2010 |
| 4.1 | Description of Common Stock | 10-K | 001-34475 | 4.1 | 03/01/2021 |
| 4.2 | Form of Omeros Corporation Common Stock Certificate | S-1/A | 333-148572 | 4.1 | 10/02/2009 |
| 4.3 | Indenture, dated as of August 14, 2020, between Omeros Corporation and Wells Fargo Bank, National Association, as trustee | 8-K | 001-34475 | 4.1 | 08/14/2020 |
| 4.4 | Second Supplemental Indenture, dated as of May 14, 2025, between the Company and Computershare Trust Company, National Association, as trustee (including the form of 9.50% Convertible Senior Notes due 2029) | 8-K/A | 001-34475 | 4.2 | 05/16/2025 |
| 10.1* | Form of Indemnification Agreement entered into between Omeros Corporation and its directors and officers | S-1 | 333-148572 | 10.1 | 01/09/2008 |
| 10.2* | 2008 Equity Incentive Plan (as amended) | 10-K | 001-34475 | 10.6 | 03/16/2017 |
| 10.3* | Form of Stock Option Award Agreement under the 2008 Equity Incentive Plan | 10-Q | 001-34475 | 10.2 | 11/07/2013 |
| 10.4* | 2017 Omnibus Incentive Compensation Plan (as amended and restated effective as of June 23, 2023) | 8-K | 001-34475 | 10.1 | 06/28/2023 |
| 10.5* | Form of Stock Option Award Agreement under the 2017 Omnibus Incentive Compensation Plan | S-8 | 333-218882 | 4.4 | 06/21/2017 |
| 10.6* | Second Amended and Restated Employment Agreement between Omeros Corporation and Gregory A. Demopulos, M.D. dated April 7, 2010 | 8-K | 001-34475 | 10.1 | 04/12/2010 |
| 10.7* | Omeros Corporation Non-Employee Director Compensation Policy | 10-K | 001-34475 | 10.11 | 03/13/2023 |
| 10.8 | Lease dated January 27, 2012 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 8-K | 001-34475 | 10.1 | 02/01/2012 |
| 10.9 | First Amendment to Lease dated November 5, 2012 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-Q | 001-34475 | 10.2 | 11/09/2012 |
| 10.10 | Second Amendment to Lease dated November 16, 2012 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-K | 001-34475 | 10.18 | 03/18/2013 |
| 10.11 | Third Amendment to Lease dated October 16, 2013 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-K | 001-34475 | 10.18 | 03/13/2014 |
| 10.12 | Fourth Amendment to Lease dated September 8, 2015 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-Q | 001-34475 | 10.3 | 11/09/2015 |
| 10.13 | Fifth Amendment to Lease dated September 1, 2016 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-Q | 001-34475 | 10.1 | 05/10/2017 |
| 10.14 | Sixth Amendment to Lease dated October 18, 2018 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-K | 001-34475 | 10.19 | 03/01/2019 |
| 10.15 | Seventh Amendment to Lease dated April 15, 2019 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-Q | 001-34475 | 10.1 | 08/08/2019 |
| 10.16 | Eighth Amendment to Lease dated October 18, 2019 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-K | 001-34475 | 10.20 | 03/02/2020 |
| 10.17 | Ninth Amendment to Lease dated January 15, 2020 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-Q | 001-34475 | 10.1 | 05/11/2020 |
| 10.18 | Tenth Amendment to Lease dated September 15, 2020 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-Q | 001-34475 | 10.1 | 11/09/2020 |
| 10.19 | Eleventh Amendment to Lease dated October 23, 2020 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-K | 001-34475 | 10.23 | 03/01/2021 |
| 10.20 | Twelfth Amendment to Lease dated January 1, 2021 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-K | 001-34475 | 10.24 | 03/01/2021 |
| 10.21 | Thirteenth Amendment to Lease dated January 1, 2021 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-Q | 001-34475 | 10.1 | 08/09/2021 |
| 10.22 | Fourteenth Amendment to Lease dated January 14, 2022 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-Q | 001-34475 | 10.1 | 05/10/2022 |
| 10.23 | Fifteenth Amendment to Lease dated November 1, 2022 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-Q | 001-34475 | 10.3 | 08/07/2024 |
| 10.24 | Sixteenth Amendment to Lease dated July 8, 2024 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-Q | 001-34475 | 10.1 | 11/13/2024 |
| 10.25 | Seventeenth Amendment to Lease dated December 18, 2024 between Omeros Corporation and BMR-201 Elliott Avenue LLC | 10-K | 001-34475 | 10.25 | 03/31/2025 |
| 10.26† | License Agreement between Omeros Corporation and Daiichi Sankyo Co., Ltd. (successor-in-interest to Asubio Pharma Co., Ltd.) dated March 3, 2010 | 10-K | 001-34475 | 10.23 | 04/01/2024 |
| 10.27† | Amendment No. 1 to License Agreement with an effective date of January 5, 2011 between Omeros Corporation and Daiichi Sankyo Co., Ltd. | 10-K | 001-34475 | 10.24 | 04/01/2024 |
| 10.28† | Amendment No. 2 to License Agreement with an effective date of January 25, 2013 between Omeros Corporation and Daiichi Sankyo Co., Ltd. | 10-K | 001-34475 | 10.25 | 04/01/2024 |
| 10.29† | Combined Development and Commercial Supply Agreement, effective as of May 16, 2018, between Omeros Corporation and Vetter Pharma international GmbH | 10-K | 001-34475 | 10.30 | 03/31/2025 | |
| 10.30† | Master Services Agreement, dated July 28, 2019, between Omeros Corporation and Lonza Biologics Tuas Pte. Ltd. | 10-Q | 001-34475 | 10.1 | 11/12/2019 | |
| 10.31† | Asset Purchase Agreement, dated as of December 1, 2021 among Omeros Corporation, Rayner Surgical Inc. and Rayner Surgical Group, Limited, as Parent Guarantor | 10-K | 001-34475 | 10.1 | 03/01/2022 | |
| 10.32† | Amended and Restated Royalty Purchase Agreement between Omeros Corporation and DRI Healthcare Acquisitions LP dated February 1, 2024 | 10-K | 001-34475 | 10.30 | 04/01/2024 | |
| 10.33† | Asset Purchase and License Agreement, dated as of October 10, 2025, between Omeros Corporation and Novo Nordisk Health Care AG | X | ||||
| 19.1 | Omeros Corporation Insider Trading Policy | 10-K | 001-34475 | 19.1 | 03/31/2025 | |
| 23.1 | Consent of Independent Registered Public Accounting Firm | X | ||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rule 13-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rule 13-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 32.1 | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 32.2 | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 97.1 | Omeros Corporation Compensation Clawback Policy | 10-K | 001-34475 | 97.1 | 04/01/2024 | |
| 101.INS | Inline XBRL Instance Document | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document | X | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X |
| 104.1 | Cover Page Interactive Data File, formatted in Inline XBRL (included in Exhibit 101) | X |
| * | Indicates management contract or compensatory plan or arrangement. |
|---|
| † | Certain identified information has been excluded from the exhibit because it both (A) is not material and (B) is the type that the registrant treats as private or confidential. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.